By Stephanie N. Rotondo
Seattle, June 1 – Trillium Therapeutics Inc. closed a $16.25 million sale of series II non-voting convertible preferred stock on Thursday, the company said in a press release.
The preferreds were sold at $5.00 a share.
Trillium also raised $13.75 million from a common stock offering, which also priced at $5.00 a share.
Cowen & Co. was the bookrunner.
The Toronto-based clinical stage immuno-oncology company will use proceeds from both offerings to advance and expand the current phase 1 trial of SIRPaFc (TTI-621) in patients with advanced hematologic malignancies, to advance and expand the current solid tumor phase 1 trial of SIRPaFc (TTI-621) in patients with relapsed and refractory, percutaneously accessible cancers through the dose escalation and expansion phases, to initiate and conduct a phase 1 trial for TTI-622 with dose escalation and expansion phase focused on combination treatment and for general corporate and working capital purposes.
| Issuer: | Trillium Therapeutics Inc.
|
| Securities: | Series II non-voting convertible preferred stock
|
| Amount: | $16.25 million, or 3.25 million shares
|
| Bookrunner: | Cowen & Co.
|
| Co-manager: | Ladenburg Thalmann & Co. Inc.
|
| Price: | $5.00 a share
|
| Pricing date: | May 26
|
| Settlement date: | June 1
|
| Stock symbol: | Nasdaq: TRIL
|
| Stock price: | $5.05 as of June 1 close
|
| Market capitalization: | $38.788 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
